Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention

Rhea-AI Summary

Ainos (NASDAQ:AIMD) has secured a Taiwan invention patent for VELDONA®, its breakthrough formulation for coronavirus treatment and prevention. The company has also filed for global patent protection under the Patent Cooperation Treaty (PCT). VELDONA® utilizes an advanced oral rapid-dissolving tablet technology that enhances immune system function and reduces the risk of coronavirus infections.

Key highlights:

• VELDONA® shows potential in activating the immune system against various coronavirus variants and preventing new infections
• The technology may extend to other viral diseases, including Hepatitis B, HIV, and various animal viruses
• Ainos believes VELDONA® could become a competitive, comprehensive antiviral therapy due to its high efficacy, safety, and low side effects

Positive

• Secured Taiwan invention patent for VELDONA®, a potential breakthrough in coronavirus treatment and prevention
• Filed for global patent protection under the Patent Cooperation Treaty (PCT)
• VELDONA® shows potential in combating various coronavirus variants and preventing new infections
• Possible applications extend to other viral diseases, expanding market potential
• Advanced oral rapid-dissolving tablet technology improves drug bioavailability and patient compliance

Negative

• None.

Medical Research Analyst

The patent granted for VELDONA® represents a significant advancement in antiviral therapy. Its unique oral rapid-dissolving tablet technology addresses key challenges in drug delivery and patient compliance. The potential for dual action in both treatment and prevention of coronavirus infections sets it apart from existing therapies.

However, it's important to note that while the patent is promising, clinical trials and regulatory approvals are still necessary before VELDONA® can be marketed. The broader application potential against other viral infections is intriguing but requires further validation. Investors should monitor upcoming clinical data and regulatory milestones to gauge the true market potential of this innovation.

Financial Analyst

This patent strengthens Ainos' intellectual property portfolio, potentially creating significant value for shareholders. The global market for antiviral drugs is substantial, with the COVID-19 pandemic highlighting the need for effective treatments. If VELDONA® proves successful in clinical trials and gains regulatory approval, it could generate substantial revenue streams for Ainos.

However, investors should be cautious. The path from patent to marketable drug is long and expensive. Ainos will likely need to secure additional funding for clinical trials and regulatory processes. The company's financial health and cash runway will be critical factors to watch in the coming quarters.

Tech Expert

The innovative oral rapid-dissolving tablet technology of VELDONA® represents a significant leap in drug delivery systems. This approach could potentially revolutionize how antiviral medications are administered, improving both efficacy and patient experience. The technology's ability to enhance bioavailability is particularly noteworthy, as it could lead to lower required doses and reduced side effects.

From a technological standpoint, this patent positions Ainos at the forefront of antiviral drug delivery innovation. However, the challenge lies in scaling up production while maintaining quality and cost-effectiveness. Investors should monitor Ainos' manufacturing capabilities and partnerships as key indicators of the technology's commercial viability.

This patent marks a major leap in Ainos' antiviral research, contributing to global efforts against coronavirus infections

SAN DIEGO, CA / ACCESSWIRE / September 3, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that its groundbreaking VELDONA® formulation has been granted an invention patent in Taiwan and has filed for global patent protection under the Patent Cooperation Treaty (PCT). This patent represents a significant milestone in the treatment and prevention of coronavirus infections.

The patented technology, titled "METHOD AND COMPOSITION OF TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION" with patent number TW202402785A, showcases a novel therapeutic approach using VELDONA® as the primary ingredient, which we believe significantly enhances immune system function and effectively reduces the risk of coronavirus infections.

After nearly four decades of relentless research, Ainos' latest breakthrough demonstrates that VELDONA® can substantially boost the immune system, providing robust protection against coronavirus infections. Unlike traditional injectable or oral therapies, VELDONA® utilizes an advanced oral rapid-dissolving tablet technology, allowing for quick absorption through the sublingual or buccal mucosa, thereby improving the drug's bioavailability and significantly enhancing patient compliance.

Further studies have shown that VELDONA® not only activates the immune system to combat various coronavirus variants but also exhibits exceptional potential in preventing new coronavirus infections, offering a dual defense mechanism that provides comprehensive protection for patients.

Moreover, we believe the application of VELDONA® extends beyond coronaviruses. Interferon has been successfully applied to treat various other viral diseases, including Hepatitis B, Hepatitis C, HIV, Feline Immunodeficiency Virus (FIV), Feline Leukemia Virus (FeLV), and Canine Parvovirus (CPV). Given the powerful immune-inducing properties of interferon, VELDONA® holds the potential to become a comprehensive antiviral therapy against multiple viral infections.

With its high efficacy, safety, and low side effects, VELDONA® is poised to become one of the most competitive antiviral drug ingredients on the market, demonstrating its tremendous potential as an all-encompassing antiviral medication.

Dr. Albert Yu, Technical Director of Pharmaceuticals and one of the primary inventors of the patent, stated, "Securing this patent is a significant milestone for the Company, and it also opens new possibilities in the global fight against coronavirus infections. We look forward to the widespread clinical application of VELDONA® worldwide and will continue to drive the development and application of more innovative drugs."

About Ainos, Inc.

Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA). The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.

The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com.

Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.

Safe Harbor Statement

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.

Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.

The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.

Investor Relations Contact

Feifei Shen
Email: IR@ainos.com

SOURCE: Ainos, Inc.

View the original press release on accesswire.com

FAQ

What is the new patent Ainos (AIMD) received for VELDONA®?

Ainos received a Taiwan invention patent for VELDONA®, titled 'METHOD AND COMPOSITION OF TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION' with patent number TW202402785A. This patent covers a novel therapeutic approach using VELDONA® as the primary ingredient for enhancing immune system function and reducing the risk of coronavirus infections.

How does VELDONA® differ from traditional coronavirus treatments?

VELDONA® utilizes an advanced oral rapid-dissolving tablet technology, allowing for quick absorption through the sublingual or buccal mucosa. This approach improves the drug's bioavailability and enhances patient compliance compared to traditional injectable or oral therapies.

What potential applications does VELDONA® have beyond coronavirus treatment?

VELDONA® shows potential for treating various other viral diseases, including Hepatitis B, Hepatitis C, HIV, Feline Immunodeficiency Virus (FIV), Feline Leukemia Virus (FeLV), and Canine Parvovirus (CPV). Its immune-inducing properties suggest it could become a comprehensive antiviral therapy against multiple viral infections.

Has Ainos (AIMD) filed for international patent protection for VELDONA®?

Yes, Ainos has filed for global patent protection for VELDONA® under the Patent Cooperation Treaty (PCT), in addition to securing the Taiwan invention patent.